Profusa Bolsters European Commercial Network with New French Distributor, MedSell




Profusa Bolsters European Commercial Network with New French Distributor, MedSell

MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union

Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France

BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a new distributor partnership in France with MedSell.  MedSell is a French company that specializes in the commercialization and distribution of innovative medical devices within the French healthcare market by leveraging tailored commercial, marketing, and market-entry support services.  As part of its portfolio, Profusa’s new partner will commercialize Lumee Oxygen tissue monitoring in France in both hospital settings and outpatient care, especially in wound care and healing clinics addressing patients with complex and chronic wounds.

Benoit Salaün, Pharm.D., Ph.D., MedSell General Manager, said, “Our collaboration with Profusa stems from our particular interest in Lumee Oxygen tissue monitoring for the large population of patients in France with Critical Limb Threatening Ischemia (CLTI). The device enables the measurement of tissue oxygen perfusion before revascularization, during endovascular or open surgical procedures, and throughout follow-up in hospitals or wound care clinics. We believe Lumee Oxygen tissue monitoring meets a critical unmet clinical need and can bring significant added value to clinicians by supporting decision-making and patient monitoring across the entire treatment pathway.”

With MedSell, Profusa builds upon previously announced distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now represent more than 200,000 CLI cases annually in the European Union.  Further, the distribution partnership with MedSell complements Profusa’s previously announced collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI). Under the agreement, Pr. Gouëffic adopts Lumee™ oxygen monitoring technology in his practice and in clinical studies that advance application of Lumee for home monitoring. Pr. Gouëffic and his associated practices account for approximately 8% of all CLTI cases in France.

“We are focused on executing on our commercial strategies, including plans to potentially achieve $200 to $250 million in revenue by 2030; capitalize on the near-term as we begin to commercialize in Europe in 2Q 2026  with the goal of addressing the US Lumee oxygen opportunity in 2027.  We expect to deliver 2026 potential revenue of $0.5 to $2 million and $9 to $13 million potential revenue in 2027,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO.  “The European clinical community continues to validate our Lumee Oxygen tissue monitoring, including recent presentations of US-based clinical trial data at Paris Vascular Insights and Leipzig Interventional Course.  We are committed to making our oxygen tissue monitoring platform easily accessible both at the clinic and at home to improve overall patient outcomes and reduce healthcare costs.”

About Profusa

Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts
Investor and Media Contacts
email:  info@coreir.com
phone:  1 (212) 655-0924

Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands




Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands

Complete Pricing Comparison Shows FDA-Approved Wegovy Access From $149 Oral to Ro’s $199 Injectable Through Telehealth as 1 in 8 Americans Now Use GLP-1 Medications

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require evaluation by a licensed clinician. Consult a qualified healthcare professional before starting any prescription treatment. This article contains affiliate links; a commission may be earned at no additional cost to the reader.

If you have searched for Wegovy pricing recently and felt like every source gives a different number, you are not alone. The landscape has shifted significantly in the final weeks of 2025, with FDA approvals, manufacturer pricing updates, and evolving telehealth access structures creating both opportunity and confusion for consumers evaluating their options.

View the current Ro Wegovy offer (official Ro page)

In this context, “best” refers to the most current, clearly published, and regulatorily approved pricing information available to consumers at the time of publication—not a value judgment, endorsement, or comparison of superiority.

This article examines publicly available pricing disclosures, FDA approvals, and telehealth access structures to help consumers independently evaluate Wegovy cost pathways in 2026.

According to Gallup data from October 2025, approximately 12.4% of U.S. adults report taking GLP-1 medications for weight loss—more than double the rate measured in early 2024. For consumers researching pricing as the new year begins, understanding what platforms have published and what regulatory changes have occurred provides essential context for informed evaluation.

December 2025 Regulatory and Pricing Timeline

The Wegovy pricing and access landscape changed substantially in the final weeks of 2025. According to published announcements and regulatory filings:

December 22, 2025: According to Novo Nordisk and independent reporting from ABC News, the FDA approved an oral Wegovy formulation—the first oral GLP-1 medication indicated for weight management in adults.

November 17, 2025: According to Novo Nordisk’s announcement, the company introduced updated cash-pay pricing structures for injectable Wegovy, with promotional pricing available through participating platforms and pharmacies.

November 2025: According to published reporting, the Trump administration announced pricing arrangements for certain GLP-1 medications through a direct-to-consumer program expected to launch in early 2026.

Early January 2026: According to Novo Nordisk, the oral Wegovy formulation is expected to become available through pharmacies and select telehealth providers, with additional pricing details to be confirmed at launch.

This timeline provides context for consumers evaluating which access pathways may align with their circumstances as 2026 begins.

View the current Ro Wegovy offer (official Ro page)

Published Wegovy Pricing Disclosures: What Platforms and Manufacturers Have Stated

Consumers encounter varying price points because multiple pricing structures exist simultaneously across different access pathways. The following reflects publicly available disclosures from manufacturers, platforms, and regulatory sources as of December 2025.

Manufacturer and Platform Disclosures:

According to Novo Nordisk’s published information, the wholesale acquisition cost for Wegovy is approximately $1,349 per month. However, various programs, partnerships, and access pathways publish substantially different consumer-facing prices.

According to Ro’s official website, the platform publishes cash-pay Wegovy pricing beginning at $199 per month for certain starter doses during a limited promotional period, with membership fees and higher dose pricing listed separately in their disclosures.

Manufacturer and platform disclosures indicate oral Wegovy cash-pay pricing beginning at published introductory levels, depending on dose and access pathway, with broader availability expected in early 2026. Higher dose pricing has not been fully disclosed at the time of this publication.

Telehealth GLP-1 Evaluation Criteria Consumers Review in 2026

Based on publicly available company disclosures at time of publication.

According to published platform information, consumers evaluating telehealth access pathways typically review medication sourcing, membership requirements, insurance compatibility, and provider access structures as part of their evaluation process.

View the current Ro Wegovy offer (official Ro page)

Understanding Oral and Injectable Wegovy: Published Information

The FDA’s December 22, 2025 approval of oral Wegovy creates a new consideration for consumers evaluating access pathways. According to manufacturer announcements, published clinical data, and platform disclosures:

Oral Wegovy (Approved December 2025):

According to Novo Nordisk’s announcement, oral Wegovy contains the same active ingredient (semaglutide) as injectable Wegovy and demonstrated weight loss outcomes in clinical trials. The company states that the oral formulation requires specific administration protocols, including being taken on an empty stomach with a small amount of water, with a 30-minute wait before eating, drinking, or taking other oral medications.

According to the OASIS 4 trial data published in The New England Journal of Medicine, participants who adhered to the oral semaglutide treatment protocol experienced average weight loss of approximately 16.6% over 64 weeks, while the overall trial population (regardless of adherence) experienced average weight loss of approximately 13.6%.

Injectable Wegovy:

According to published clinical trial data from the STEP 1 trial, participants taking injectable Wegovy 2.4 mg weekly experienced average weight loss of approximately 14.9% over 68 weeks alongside lifestyle modifications.

Format Considerations:

According to published information, both formulations require evaluation by a licensed clinician and are indicated for the same patient populations. Consumers typically discuss format preferences and individual circumstances with their healthcare provider.

Ro Wegovy Access: Published Pricing and Program Structure

For consumers specifically evaluating Ro, the following reflects the company’s published disclosures as of December 2025.

Medication Pricing (Cash-Pay):

According to Ro’s official website:

• Ro lists cash-pay Wegovy pricing beginning at $199 per month for certain starter doses for a limited promotional period, with higher doses priced differently, according to its published disclosures
• The promotional pricing is noted as available through March 31, 2026
• Higher doses (including 2.4 mg) are listed at different price points

Membership Structure:

According to Ro’s published information, the Ro Body membership is required for weight loss program access:

• First month membership listed at $45
• Ongoing monthly membership listed at $145

Published Membership Inclusions:

According to Ro’s website, the membership includes licensed provider access, messaging availability, health coaching, monitoring tools, and periodic check-ins. Consumers typically review the full scope of included services on the platform’s official website.

Medication Sourcing:

According to Ro’s disclosures, Wegovy accessed through their platform is sourced through NovoCare Pharmacy, which is operated by Novo Nordisk. The company states this provides authentic, FDA-approved Wegovy.

Insurance Pathway:

According to Ro’s published information, the platform offers an insurance concierge service to assist with prior authorization processes. The company notes certain limitations regarding government insurance programs.

Ro states on its official website that the platform cannot coordinate coverage for Medicare, Medicaid, or VA plans for GLP-1 medications used for weight loss. Consumers with government insurance are advised to review their specific plan details and explore options independently.

View the current Ro Wegovy offer (official Ro page)

FDA Eligibility Criteria: Who Wegovy Is Indicated For

According to FDA prescribing information, Wegovy is indicated for specific patient populations. Consumers typically review eligibility criteria, insurance compatibility, and ongoing program requirements directly with the platform and a licensed clinician.

FDA-Approved Indications:

According to FDA prescribing information, Wegovy is indicated for:

Chronic Weight Management: Adults with obesity (BMI of 30 or greater) OR adults with overweight (BMI of 27 or greater) who also have at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. According to prescribing information, treatment should be used alongside a reduced-calorie diet and increased physical activity.

Cardiovascular Risk Reduction: Adults with established cardiovascular disease and either obesity or overweight, to reduce the risk of major adverse cardiovascular events.

BMI Reference Points:

Contraindications:

According to FDA prescribing information, Wegovy should NOT be used by individuals who:

• Have a personal or family history of medullary thyroid carcinoma (MTC)
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Have known hypersensitivity to semaglutide or any product components
• Are pregnant or planning to become pregnant (discontinuation is recommended at least 2 months before planned pregnancy)
• Are breastfeeding

Consumers with questions about eligibility or contraindications should consult directly with a licensed healthcare provider.

Understanding the Regulatory Landscape: FDA-Approved vs. Compounded Medications

Consumers researching weight loss medication options may encounter both FDA-approved branded medications and compounded formulations. Understanding the regulatory distinction provides important context for evaluation.

FDA-Approved Medications:

According to FDA communications, approved medications have undergone review for safety, efficacy, and manufacturing quality. Examples include Wegovy, Ozempic, Zepbound, and Mounjaro, which carry specific FDA-approved indications and labeling.

Compounded Medications:

The FDA has stated that compounded versions of semaglutide are not reviewed or approved as finished products for safety, effectiveness, or quality.

According to FDA communications, compounded medications are prepared by licensed pharmacies based on individual prescriptions. While the active pharmaceutical ingredients may be the same, compounded products have not undergone FDA review as finished formulations.

Regulatory Context:

According to published FDA communications, the agency declared the semaglutide shortage resolved in February 2025, which affected compounding permissions. According to regulatory analysis, litigation challenging these determinations continues.

According to FDA safety communications, patients considering compounded options should ask their provider or compounder how to measure and administer the intended dose and which ingredient form is being used.

Consumers evaluating different access pathways should discuss regulatory considerations with their healthcare provider as part of their decision-making process.

Clinical Trial Context: Published Weight Loss Data

For consumers researching effectiveness, understanding what clinical trials demonstrated provides context—while recognizing that individual outcomes vary significantly.

Injectable Wegovy (STEP 1 Trial):

According to the STEP 1 clinical trial published in The New England Journal of Medicine:

• Participants taking Wegovy 2.4 mg weekly experienced average weight loss of approximately 14.9% over 68 weeks
• According to the published data, 86% of participants lost at least 5% of body weight
• The trial included lifestyle modifications alongside medication

Oral Wegovy (OASIS 4 Trial):

According to the OASIS 4 trial published in The New England Journal of Medicine:

• Participants who adhered to the oral treatment protocol experienced average weight loss of approximately 16.6% over 64 weeks
• The overall trial population (regardless of adherence) experienced average weight loss of approximately 13.6%
• According to the manufacturer, results were considered comparable to injectable formulation trials, though the studies were conducted separately

Important Clinical Trial Context:

According to standard clinical research principles, trial results represent population averages from controlled conditions with specific patient populations, lifestyle interventions, and medical supervision. Individual outcomes vary significantly based on adherence, lifestyle factors, medical history, and biological response. Clinical trial results should not be interpreted as guarantees of individual outcomes.

Safety Information: What Consumers Should Know

According to FDA prescribing information and published clinical trial data, Wegovy carries specific safety considerations that consumers should review with their healthcare provider.

Boxed Warning:

According to FDA prescribing information, Wegovy carries a boxed warning regarding thyroid C-cell tumors:

In rodent studies, semaglutide caused thyroid tumors, including thyroid cancer. According to the FDA, it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in patients with personal or family history of MTC or MEN 2.

Commonly Reported Side Effects:

According to clinical trial data, commonly reported side effects include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Headache and fatigue

According to prescribing information, gastrointestinal side effects are most commonly reported when starting treatment or increasing doses and may improve as the body adjusts.

Serious Side Effects:

According to prescribing information, serious side effects may include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, increased heart rate, and depression or suicidal thoughts. Consumers should seek medical attention for severe symptoms.

Medical Supervision Requirement:

According to FDA prescribing information, Wegovy requires ongoing medical supervision. Consumers should discuss the full scope of potential benefits and risks with a licensed healthcare provider before and during treatment.

Consumer Self-Assessment Framework

Rather than product recommendations, this framework helps consumers evaluate whether further exploration of GLP-1 medication pathways may be appropriate for their circumstances.

Consumers May Consider Further Evaluation If They:

• Meet FDA eligibility criteria (BMI 30+ or BMI 27+ with weight-related medical condition)
• Have discussed weight management options with a healthcare provider
• Understand that GLP-1 medications work alongside lifestyle modifications
• Can evaluate the financial commitment involved in ongoing treatment
• Are comfortable with telehealth-based or in-person medical care models

Consumers Should Consult Healthcare Providers If They Have:

• Any contraindications listed in prescribing information
• Uncertainty about eligibility or appropriateness
• Questions about interactions with current medications
• Concerns about side effects or monitoring requirements
• Government insurance and need guidance on coverage options

Questions Consumers Typically Discuss With Providers:

• Am I a candidate based on BMI and health factors?
• What are the potential benefits and risks for my specific situation?
• What monitoring and follow-up would be required?
• How do different access pathways compare for my circumstances?
• What is the expected timeline and financial commitment?

Consumers typically review eligibility criteria, insurance compatibility, and ongoing program requirements directly with the platform and a licensed clinician.

View the current Ro Wegovy offer (official Ro page)

Frequently Asked Questions

What has Ro published regarding Wegovy pricing?

According to Ro’s official website, the platform lists cash-pay Wegovy pricing beginning at $199 per month for certain starter doses during a limited promotional period. The Ro Body membership is listed at $45 for the first month and $145 monthly thereafter. Higher doses and ongoing pricing are listed separately in their disclosures.

What is the source of Wegovy through Ro?

According to Ro’s published disclosures, Wegovy accessed through their platform is sourced through NovoCare Pharmacy, which is operated by Novo Nordisk.

Is Ro a licensed telehealth platform?

According to publicly available information, Ro is a telehealth company that has operated since 2017 and partners with licensed healthcare providers across all 50 U.S. states.

What has been published regarding oral Wegovy availability?

According to Novo Nordisk’s announcement, the oral Wegovy formulation is expected to become available through pharmacies and select telehealth providers in early January 2026. Consumers should verify availability directly with platforms.

What are the insurance limitations through Ro?

According to Ro’s website, the platform cannot coordinate coverage for Medicare, Medicaid, or VA plans for GLP-1 medications used for weight loss. The company offers an insurance concierge service for consumers with commercial insurance.

How do clinical trial results relate to individual outcomes?

According to standard clinical research principles, trial results represent population averages and do not guarantee individual outcomes. Results vary based on adherence, lifestyle factors, medical history, and biological response.

Summary: Evaluating Wegovy Access Pathways in 2026

The weight loss medication landscape has evolved substantially as 2026 begins. For consumers evaluating Wegovy access pathways, this analysis has examined:

What Has Been Published:

• Manufacturer and platform pricing disclosures
• FDA approval updates including oral formulation
• Telehealth access structures and membership requirements
• Clinical trial data and safety information

What Consumers Typically Evaluate:

• Eligibility based on FDA indications
• Access pathway alignment with individual circumstances
• Financial commitment and insurance considerations
• Format preferences (oral vs. injectable)
• Provider access and support structures

Regulatory Context:

• FDA-approved medications have undergone safety and efficacy review
• Compounded formulations have different regulatory status
• The landscape continues to evolve with new approvals and pricing structures

For consumers interested in exploring Ro’s published Wegovy pricing and access structure, view the current Ro Wegovy offer (official Ro page) to review current disclosures and evaluate whether further exploration aligns with individual circumstances.

Contact Information

According to Ro’s website, consumers can access platform information and support through:

Website: ro.co/weight-loss

Emai: care@ro.co

Support: Available through the Ro platform

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are based on published clinical research and do not guarantee individual outcomes. GLP-1 medications require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Safety Information: Wegovy (semaglutide) carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and serious allergic reactions. For complete safety information, review the full prescribing information and consult your healthcare provider.

Results Disclaimer: Individual results will vary based on factors including age, starting weight, baseline health condition, lifestyle factors, consistency of use, adherence to diet and exercise recommendations, genetic factors, current medications, and other individual variables. Clinical trial results represent averages and are not guarantees of individual outcomes. Results are not guaranteed. Prescription approval is not guaranteed; licensed medical providers make final determinations based on individual medical appropriateness.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research, manufacturer announcements, clinical trial data, and publicly available platform information.

Pricing Disclaimer: All prices, promotional offers, and terms mentioned were accurate based on published information at the time of publication (December 2025) but are subject to change without notice. Always verify current pricing and terms on official websites before making decisions.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information, manufacturer announcements, clinical trial publications, and platform disclosures. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Ro, Novo Nordisk, their insurance provider, and their healthcare provider before making decisions.

Insurance Coverage Note: Insurance coverage for GLP-1 medications varies significantly by plan. Many commercial insurance plans require prior authorization for weight loss medications. Medicare Part D plans generally do not cover GLP-1 medications when prescribed for weight loss. Coverage may apply for cardiovascular risk reduction in patients with established heart disease. Medicaid coverage varies by state. Always confirm benefits directly with your insurer before beginning treatment.

Telehealth Platform Disclosure: According to standard telehealth industry structure, Ro operates as a technology platform that coordinates care. Licensed medical providers affiliated with Ro make independent prescribing decisions. NovoCare Pharmacy, operated by Novo Nordisk, dispenses medications. These are separate entities with distinct roles in the care process.

Analysis based on information available as of December 30, 2025. Verify current information directly with Ro, manufacturers, insurance providers, and healthcare professionals.

CONTACT: Email: care@ro.co

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study




Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

Industry Analysis Examines How Cost-Conscious Patients Navigate GLP-1 Options After FDA Oral Semaglutide Approval — Platform Verification Methods, Compounded Medication Regulatory Status, and Third-Party Certification Signals Explored

Bluffdale, UT, Dec. 30, 2025 (GLOBE NEWSWIRE) — The phrase “best Wegovy alternative” reflects how millions of patients search for weight-loss medication information online, particularly during the New Year health reset. In this context, “best” does not indicate a ranking or recommendation, but rather signals an exploration of what options exist, how they differ, and what consumers should independently verify before making healthcare decisions.

Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting any prescription medication. Compounded medications are not FDA-approved as finished products. If you purchase through links in this article, a commission may be earned at no additional cost to you.

Patients researching GLP-1 access pathways can view the current Direct Meds offer (official Direct Meds page) to review published disclosures and platform credentials.

Why “Best Wegovy Alternative” Searches Are Spiking in January 2026

The post-holiday period is widely associated with elevated interest in weight-loss searches and New Year health goals. According to a December 2025 YouGov survey, exercising more topped Americans’ New Year’s resolutions for 2026, with 25% of respondents listing it as their primary goal. A separate Statista survey found that approximately 48% of respondents ranked fitness goals as their highest priority heading into the new year.

This seasonal search volume coincides with significant developments in the GLP-1 medication landscape. On December 22, 2025, the FDA approved an oral semaglutide option for chronic weight management, expanding GLP-1 access beyond injectable formulations. According to the Gallup Health and Well-Being Index from October 2025, approximately 12.4% of U.S. adults now report taking GLP-1 drugs for weight loss, more than double the 5.8% measured in February 2024.

For individuals researching weight-loss medication options, this analysis provides information on what different access pathways exist, what published regulatory and clinical data shows, and what verification methods consumers use when evaluating telehealth platforms independently.

What Changed in the GLP-1 Landscape

The FDA’s December 22, 2025 approval expanded GLP-1 access beyond injectable formulations by adding an oral semaglutide option for chronic weight management, based on FDA-reviewed labeling and published trial data. According to Novo Nordisk’s announcement, the company plans a full U.S. launch in early January 2026.

Oral GLP-1 options have specific administration requirements described in FDA-approved labeling, which patients should review with a licensed clinician or pharmacist.

Injectable GLP-1 medications including Wegovy and Zepbound remain available through traditional healthcare channels and select telehealth platforms. Manufacturers and select cash-pay programs have published varying out-of-pocket price points for FDA-approved GLP-1 medications, and these terms can change. Readers should confirm the latest pricing directly with the manufacturer or the dispensing channel before making any decision.

The Three Access Pathways Patients Are Evaluating

Patients researching GLP-1 medications in 2026 typically encounter three distinct access pathways, each with different regulatory status and considerations.

FDA-Approved Brand-Name Medications:

These include injectable Wegovy and an FDA-approved oral semaglutide option for chronic weight management, as well as Zepbound, Ozempic when prescribed off-label for weight loss, and Mounjaro. These products have undergone comprehensive FDA review for safety, efficacy, and manufacturing quality. They carry specific FDA-approved indications and extensive clinical trial data.

Compounded GLP-1 Medications via Telehealth:

Telehealth platforms facilitate access to compounded semaglutide and tirzepatide prepared by licensed compounding pharmacies based on individual prescriptions from licensed providers. According to FDA guidance, compounded medications are not FDA-approved as finished products and have not undergone FDA review for safety, efficacy, or quality as finished formulations.

Insurance-Covered Treatment Through Traditional Healthcare:

Patients with qualifying insurance coverage may access brand-name medications through traditional healthcare providers. However, according to the KFF Health Tracking Poll, about half of adults who have taken GLP-1 drugs reported difficulty affording the cost, and many insurance plans either do not cover weight loss medications or require extensive prior authorization processes.

How Consumers Verify Telehealth GLP-1 Claims in 2026

As the telehealth GLP-1 market has expanded, consumers have developed verification practices to evaluate platform claims independently. The following describes common verification methods based on publicly available information.

Third-Party Certification:

LegitScript is a certification body that evaluates telehealth platforms against published standards for legal compliance, prescribing protocols, and patient safety. Platforms that maintain LegitScript certification have undergone independent verification. Consumers can verify certification status using LegitScript’s website certification status tool.

Pharmacy Disclosure:

Consumers evaluate whether telehealth platforms publicly disclose their pharmacy partners by name and regulatory category. Licensed 503A compounding pharmacies prepare medications for individual patients under state and federal guidelines. Named pharmacy disclosure allows consumers to independently verify pharmacy credentials.

Provider Independence:

Consumers evaluate whether platforms clearly separate the technology platform function from independent medical decision-making. Platforms that disclose their three-entity model (platform, independent providers, partner pharmacies) provide transparency about how prescribing decisions are made.

Regulatory Transparency:

Consumers evaluate whether platforms acknowledge the regulatory status of compounded medications, including that they are not FDA-approved as finished products. Platforms that include clear regulatory disclosures demonstrate transparency about product classification.

Third-Party Review Platforms:

Independent consumer review platforms such as Trustpilot allow consumers to view user-submitted feedback. Review platforms reflect individual experiences that may vary. Consumers can review current entries directly to form independent assessments.

Direct Meds as a Verification Case Study

The following examines Direct Meds as a case study in how consumers apply verification methods to telehealth platforms. This section describes publicly available disclosures and does not constitute an endorsement or recommendation.

Platform Overview:

According to its published materials, Direct Meds is a telehealth platform based in Bluffdale, Utah that connects patients with licensed healthcare providers who evaluate submitted information and determine whether a prescription is medically appropriate based on independent clinical judgment. The company states it has served over 53,000 customers. Additional context regarding the platform’s operational structure and LegitScript certification status has been documented in prior industry coverage.

LegitScript Certification:

According to the company’s published disclosures, Direct Meds maintains LegitScript certification. Consumers can verify certification status using LegitScript’s website certification status tool.

Entity Separation Disclosure:

According to the company’s terms of use and FAQ section, the Direct Meds approach involves three separate entities: the technology platform that coordinates logistics and customer service, independent licensed healthcare providers who make prescribing decisions, and partner compounding pharmacies that fulfill prescriptions.

Pharmacy Partner Disclosure:

According to the company’s FAQ, prescriptions are fulfilled by 503A compounding pharmacies based in the United States. The company identifies CraftedRx in Warrenton, Missouri and ChemistryRx in Folcroft, Pennsylvania as its pharmacy partners. Consumers can independently verify these pharmacy credentials.

Medical Director Oversight:

According to the company’s disclosures, Direct Meds has its own medical director who is a practicing physician and has reviewed the doctor and pharmacy network.

Medication Documentation:

According to the company’s website, Certificate of Analysis documents are published showing purity testing results for formulations.

Third-Party Review Presence:

Trustpilot displays 6,000+ user-submitted reviews for Direct Meds. Review platforms reflect individual experiences that may vary, and readers should review current entries directly.

Pricing Disclosure:

According to Direct Meds’ website at the time of publication, the platform lists compounded semaglutide pricing starting at $197 per month. Pricing and availability may change, and readers should confirm current terms directly with the company.

Patients researching platform credentials can view the current Direct Meds offer (official Direct Meds page) to review published disclosures.

Clinical Trial Context: FDA-Approved Products Only

For individuals evaluating options with their healthcare providers, understanding what clinical trials demonstrated provides context. The following summarizes published research on FDA-approved formulations only.

Oral Semaglutide (Wegovy Pill) – FDA Approved December 2025:

According to the OASIS 4 trial published in the New England Journal of Medicine, participants who took the Wegovy pill experienced 13.6% mean weight loss over approximately 64 weeks when including all participants regardless of adherence, compared to 2.2% for those taking placebo. When only including participants who adhered to treatment protocol, mean weight loss was 16.6%. One in three participants experienced 20% or greater weight loss.

According to Dr. Sean Wharton, lead study author quoted in Novo Nordisk’s announcement, oral semaglutide 25 mg represents a significant advancement in obesity treatment.

Injectable Semaglutide (Wegovy) – FDA Approved 2021:

According to clinical trial data, injectable Wegovy demonstrated approximately 15% mean weight loss compared to placebo over 68 weeks. The SELECT trial also demonstrated cardiovascular risk reduction benefits.

Tirzepatide (Zepbound) – FDA Approved 2023:

According to clinical trials cited by multiple sources including NBC News, tirzepatide showed approximately 21% to 22.5% mean weight loss on its highest dose after 72 weeks, compared to approximately 3% for placebo.

Clinical Trial Firewall:

The outcomes referenced above come from clinical trials of FDA-approved formulations conducted under controlled conditions and do not establish expected results for compounded medications, which are not FDA-approved as finished products.

Compounded Medication Regulatory Context

Individuals considering compounded GLP-1 access should understand the regulatory framework that applies to these products.

FDA Non-Approval Status:

Compounded medications are not FDA-approved as finished products. They have not undergone FDA review for safety, effectiveness, or quality as finished formulations. According to FDA communications, compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved medication.

Evolving Enforcement Landscape:

The FDA declared semaglutide and tirzepatide shortages resolved in 2025, which affects the regulatory framework under which compounding is permitted. According to FDA guidance, following shortage resolution, compounding is generally permitted only when a prescriber determines a patient has specific medical needs that cannot be met by FDA-approved drugs.

Ongoing Litigation:

According to FDA communications and independent reporting, litigation challenging shortage determinations is ongoing. The regulatory status of compounded GLP-1 medications continues to evolve. Patients should verify the most current information about any platform’s compliance and regulatory standing.

Salt Form Considerations:

According to FDA communications, the agency has noted that some compounded products may use salt forms such as semaglutide sodium or semaglutide acetate. The FDA has stated it is not aware of a basis for compounding using those salts.

Search-Driven FAQ: Neutral, Informational

Is compounded semaglutide FDA approved?

No. Compounded semaglutide is not FDA-approved as a finished product. Compounded medications have not undergone FDA review for safety, effectiveness, or quality as finished formulations. Only brand-name products such as Wegovy and Ozempic have completed the FDA approval process.

Why do GLP-1 medication prices vary so widely?

Brand-name FDA-approved medications include costs for clinical trials, FDA approval processes, and manufacturing under FDA oversight. Compounded medications are prepared by pharmacies using active pharmaceutical ingredients without these cost structures. The price difference reflects different regulatory classifications and development pathways.

What does LegitScript certification mean?

LegitScript is an independent certification body that evaluates telehealth platforms against published standards for legal compliance, prescribing protocols, and patient safety. Certification indicates a platform has undergone third-party verification. Consumers can verify certification status using LegitScript’s website certification status tool.

What is a 503A compounding pharmacy?

According to FDA guidance, 503A compounding pharmacies prepare medications for individual patients based on valid prescriptions from licensed practitioners. These pharmacies operate under state and federal guidelines. The 503A designation distinguishes them from 503B outsourcing facilities, which can produce larger quantities without individual prescriptions.

What safety considerations apply to GLP-1 medications?

According to FDA-approved labeling, GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. These medications are contraindicated for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects include nausea, vomiting, diarrhea, and constipation. Patients should discuss all safety considerations with healthcare providers.

Contact Information

Direct Meds, LLC

14572 S 790 W #A100

Bluffdale, UT 84065

Phone: 888-696-7176

Email: help@directmeds.com

Patients can view the current Direct Meds offer (official Direct Meds page) to review platform credentials and current disclosures.

Disclaimers

Compounded Medication Regulatory Notice: Direct Meds facilitates access to compounded prescription medications prepared by licensed 503A compounding pharmacies based on individual prescriptions from licensed providers. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality before being dispensed. The FDA has expressed concerns about compounded GLP-1 medications and recommends that patients obtain prescriptions from their doctor and fill them at a state-licensed pharmacy when FDA-approved products are available and can meet the patient’s needs. Only a licensed clinician can determine whether a compounded medication is appropriate for an individual patient.

Telehealth Platform Notice: Direct Meds is a telehealth platform that facilitates connections between patients and independent licensed healthcare providers. Direct Meds is not itself a healthcare provider and does not make medical decisions. Independent licensed medical providers review patient information and determine whether prescriptions are appropriate based on their professional medical judgment. The platform cannot guarantee that any individual will receive a prescription, as that determination rests entirely with the evaluating clinician.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The descriptions of potential benefits are based on published clinical research on FDA-approved formulations and do not guarantee individual outcomes. GLP-1 medications may cause serious side effects including potential thyroid C-cell tumors. Do not use if you or your family have a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Consult a qualified healthcare professional before starting any prescription medication or making changes to existing treatment.

Clinical Trial Context Notice: Weight loss percentages and other outcomes referenced in this article are derived from published clinical trials conducted under controlled conditions with specific patient populations using FDA-approved formulations. These results represent population averages and are not predictive of individual outcomes. Individual results vary significantly based on adherence, lifestyle factors, medical supervision, and biological response. Clinical trial outcomes do not guarantee any specific individual result and do not establish outcomes for compounded medications.

Third-Party Verification Notice: References to LegitScript certification and Trustpilot are based on publicly available information as of December 2025. These third-party platforms operate independently and their ratings reflect proprietary methodologies and user-submitted reviews. Status may change over time. Consumers should verify current status directly with these platforms.

Results Disclaimer: Individual weight loss results vary based on numerous factors including starting weight, adherence to medication protocols, dietary modifications, physical activity levels, genetic factors, concurrent health conditions, other medications, and individual metabolic factors. Results are not guaranteed, and some patients may not experience meaningful weight loss or may discontinue treatment due to side effects or other factors.

Regulatory Scrutiny Acknowledgment: The GLP-1 telehealth and compounding industry has been under increased regulatory scrutiny. Regulatory requirements, enforcement policies, and the legal status of compounded GLP-1 medications continue to evolve. Patients should review the most current information about any telehealth service’s compliance, regulatory standing, and operational status before proceeding.

Affiliate Disclosure: This article contains affiliate links. If you access services through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the company’s official website, FDA publications, manufacturer announcements, published clinical trial data, and independent surveys.

Pricing Disclaimer: Pricing information referenced was based on published website information and manufacturer announcements as of December 2025 and is subject to change without notice. Always verify current pricing and terms directly with companies before making decisions.

Trademark Notice: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trustpilot is a registered trademark of Trustpilot A/S. LegitScript is a registered trademark of LegitScript LLC. Direct Meds is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or the manufacturers of any FDA-approved GLP-1 medications. Compounded semaglutide and tirzepatide are not the same as these FDA-approved branded products.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy based on publicly available information at the time of publication in December 2025. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of information provided. Readers are encouraged to verify all details directly with Direct Meds, healthcare providers, and relevant regulatory authorities before making healthcare decisions.

Insurance Coverage Note: Many direct-to-consumer prescription weight loss medications are not covered by traditional insurance plans, but coverage policies vary. Medicare coverage for weight-loss-only use has historically been limited. Always confirm benefits directly with your insurer.

Independent Data Sources Referenced

FDA and Regulatory Sources: FDA December 22, 2025 approval of an oral semaglutide option for chronic weight management (per FDA-reviewed labeling and manufacturer communications); FDA guidance on compounded medications and 503A pharmacy regulations; FDA shortage declarations and enforcement discretion communications

Novo Nordisk Official Sources: Company press releases and announcements regarding OASIS 4 trial data, pricing structures, and availability timeline

Eli Lilly Official Sources: LillyDirect pricing disclosures for Zepbound

Published Clinical Data: OASIS 4 trial published in New England Journal of Medicine; Wegovy injection phase 3 trials; Zepbound tirzepatide phase 3 trials

Independent Surveys and Research: Gallup Health and Well-Being Index October 2025; YouGov survey December 2025; Statista survey; KFF Health Tracking Poll

Expert Sources: Dr. Sean Wharton, lead study author

News Coverage: ABC News, NBC News, NPR, CBS News reporting on FDA approval

Company Disclosures: Direct Meds official website for platform terms, pricing, FAQ information, and regulatory disclosures

All regulatory and clinical claims are attributed to primary sources.

Source: Industry analysis based on FDA announcements, published clinical trial data, manufacturer pricing disclosures, company website information, and independent surveys including Gallup Health and Well-Being Index, YouGov, Statista, and KFF Health Tracking Poll.

CONTACT: Phone: 888-696-7176
Email: help@directmeds.com

Cannabix Secures First Distributor Order for BreathLogix Alcohol Screening Devices in Australia




Cannabix Secures First Distributor Order for BreathLogix Alcohol Screening Devices in Australia

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings

VANCOUVER, British Columbia, Dec. 30, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) a developer of marijuana and alcohol breath testing devices, is pleased to announce that it has received its first product orders for BreathLogix devices and related accessories from its exclusive distribution partner in Australia, Breathalyser Sales & Service Pty Ltd. (“Breathalyser SSP”). This order represents Cannabix’s first international distributor order for its BreathLogix alcohol screening product line.

Earlier this year, Cannabix entered into an exclusive distribution agreement with Breathalyser SSP for Australia, New Zealand, and the Pacific Islands to represent the Company’s BreathLogix autonomous (unmanned) alcohol breathalyzer devices (see Figures 1 and 2).

BreathLogix devices provide rapid breath alcohol checks, capture a photo of the user simultaneously, and deliver real-time alerts to managers—helping prevent workplace injuries and property damage caused by alcohol impairment.

Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use for the Australian market. The company operates regional offices in Perth, Melbourne, and Brisbane and serves clients across sectors including mining, oil and gas, industrial, trucking, warehousing, and technology.

Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is excited to receive first orders from Australia for its BreathLogix Alcohol devices as the Company works to deliver innovative new technologies to market. Breathalyser Sales & Service Pty Ltd has many years of experience with various industries deploying breath alcohol testing systems to improve worker safety.”

Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia’s oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, unmanned employee alcohol screening is a major segment of our business.”

Figure 1. BreathLogix Alcohol Screening Devices

Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening

BreathLogix Alcohol Screening Devices

BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.

The Company reports that it will not proceed with the previously announced non-brokered LIFE private placement. Recent orders for the BreathLogix product line, coupled with increased ramp-up activity from distribution partners for the Marijuana Breath Test solution, indicate that the Company’s near-term capital requirements will be reassessed in early 2026.

The Company has entered into an arm’s length 30-day investor awareness campaign with ShareholdersIPR LLC. ShareholdersIPR, will provide a research report, help disseminate the report through social media and online web forums (“Services”). As consideration for the Services, the company will pay USD $2,450. The Company will not issue any securities to ShareholdersIPR as compensation for its Services. The principal of ShareholdersIPR LLC is Thomas K. Shea (thomas@shareholdersipr.com, 404-314-5580, Marietta, Georgia).

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company’s products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/bbe8a96d-67b5-4446-902b-98bcd9705293 

https://www.globenewswire.com/NewsRoom/AttachmentNg/aa691629-ff88-4889-b0bf-665f8d3f1b60

Cannabix Secures First Distributor Order for BreathLogix Alcohol Screening Devices in Australia




Cannabix Secures First Distributor Order for BreathLogix Alcohol Screening Devices in Australia

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings

VANCOUVER, British Columbia, Dec. 30, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) a developer of marijuana and alcohol breath testing devices, is pleased to announce that it has received its first product orders for BreathLogix devices and related accessories from its exclusive distribution partner in Australia, Breathalyser Sales & Service Pty Ltd. (“Breathalyser SSP”). This order represents Cannabix’s first international distributor order for its BreathLogix alcohol screening product line.

Earlier this year, Cannabix entered into an exclusive distribution agreement with Breathalyser SSP for Australia, New Zealand, and the Pacific Islands to represent the Company’s BreathLogix autonomous (unmanned) alcohol breathalyzer devices (see Figures 1 and 2).

BreathLogix devices provide rapid breath alcohol checks, capture a photo of the user simultaneously, and deliver real-time alerts to managers—helping prevent workplace injuries and property damage caused by alcohol impairment.

Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use for the Australian market. The company operates regional offices in Perth, Melbourne, and Brisbane and serves clients across sectors including mining, oil and gas, industrial, trucking, warehousing, and technology.

Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is excited to receive first orders from Australia for its BreathLogix Alcohol devices as the Company works to deliver innovative new technologies to market. Breathalyser Sales & Service Pty Ltd has many years of experience with various industries deploying breath alcohol testing systems to improve worker safety.”

Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia’s oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, unmanned employee alcohol screening is a major segment of our business.”

Figure 1. BreathLogix Alcohol Screening Devices

Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening

BreathLogix Alcohol Screening Devices

BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.

The Company reports that it will not proceed with the previously announced non-brokered LIFE private placement. Recent orders for the BreathLogix product line, coupled with increased ramp-up activity from distribution partners for the Marijuana Breath Test solution, indicate that the Company’s near-term capital requirements will be reassessed in early 2026.

The Company has entered into an arm’s length 30-day investor awareness campaign with ShareholdersIPR LLC. ShareholdersIPR, will provide a research report, help disseminate the report through social media and online web forums (“Services”). As consideration for the Services, the company will pay USD $2,450. The Company will not issue any securities to ShareholdersIPR as compensation for its Services. The principal of ShareholdersIPR LLC is Thomas K. Shea (thomas@shareholdersipr.com, 404-314-5580, Marietta, Georgia).

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company’s products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/bbe8a96d-67b5-4446-902b-98bcd9705293 

https://www.globenewswire.com/NewsRoom/AttachmentNg/aa691629-ff88-4889-b0bf-665f8d3f1b60

AIM ImmunoTech Announces Stock Dividend




AIM ImmunoTech Announces Stock Dividend

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) —  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026.

Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025.

Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders’ book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder’s behalf. The stock dividend is administered by EQ, the Company’s transfer agent.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

AIM ImmunoTech Announces Stock Dividend




AIM ImmunoTech Announces Stock Dividend

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) —  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026.

Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025.

Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders’ book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder’s behalf. The stock dividend is administered by EQ, the Company’s transfer agent.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Profound Medical Corp. Announces Closing of Private Placement




Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).

Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45 million.

The common shares sold pursuant to the Offering are subject to a hold period of four months plus one day from the closing date of the Offering under Canadian securities laws.

The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.

The securities being offered under the Offering have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement within four months from the closing date of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Company’s securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds from the Offering and the intended registration of the common shares. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Profound Medical Corp. Announces Closing of Private Placement




Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).

Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45 million.

The common shares sold pursuant to the Offering are subject to a hold period of four months plus one day from the closing date of the Offering under Canadian securities laws.

The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.

The securities being offered under the Offering have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement within four months from the closing date of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Company’s securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds from the Offering and the intended registration of the common shares. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference




Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com